First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    CRISPR Therapeutics AG

    CRSP · 11 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 11 macro, policy, and market developments to CRISPR Therapeutics AG since 2026-09-09. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for CRSP yet, so no modelled value is shown. The CRSP valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run CRSP on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for CRSP. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump

      Direct commercial success and regulatory approval for key product. Increased market penetration and addressable patient population.

      · Moves future revenue growth rates, peak sales estimates, probability of success for pipeline assets (due to validation of platform)

    • Open question

      Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline

      Second-order effect: Investor sentiment and competitive landscape in the gene editing and CAR T space. Positive or negative news from Cellectis could spill over to peers.

      · Moves investor sentiment biotech sector, perceived risk gene editing platform

    What changed, by assumption

    Future revenue growth rates
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
    Peak sales estimates for casgevy
    • 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
    • 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
    • 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    Probability of success for pipeline assets
    • 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
    Investor sentiment
    • 2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
    Investor sentiment biotech sector
    • 2026-09-12Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29uniQure N.V. Reports 48-Month Data for AMT-130 in Huntington’s Diseasemixed1-3m0.20
    2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine AdjuvantsBullish3-12m0.30
    2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthBullish1-5y0.40
    2026-09-12Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipelinemixed1-3m0.30
    2026-09-12Cellectis Schedules September 14 Business and CAR T Pipeline Updatewatch1-5d0.30
    2026-09-12Cellectis sets September 14 business update on CAR-T and gene editing pipelinewatch1-5d0.20
    2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales JumpBullish3-12m0.90
    2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+Bullish3-12m0.80
    2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MBullish1-3m0.80
    2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyBullish3-12m0.90
    2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76MBullish1-3m0.90